Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (19)

2022

  1. Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients

    Pharmaceutics, Vol. 14, Núm. 4

2020

  1. Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy

    European Journal of Pharmaceutical Sciences, Vol. 153

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2011

  1. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

2009

  1. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2005

  1. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

  2. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

2004

  1. Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos

    Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101

2002

  1. Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations

    Clinical Pharmacokinetics, Vol. 41, Núm. 2, pp. 115-135

1999

  1. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data

    Biopharmaceutics and Drug Disposition, Vol. 20, Núm. 5, pp. 233-240

  2. Valproate population pharmacokinetics in children

    Journal of Clinical Pharmacy and Therapeutics, Vol. 24, Núm. 1, pp. 73-80

1997

  1. Carbamazepine population pharmacokinetics in children: Mixed-effect models

    Therapeutic Drug Monitoring, Vol. 19, Núm. 2, pp. 132-139

1996

  1. Application of population pharmacokinetics to the optimization of theophylline therapy

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 2, pp. 113-125

  2. FARMACOCINETICA CLINICA DE LOS INHIBIDORES SELECTIVOS DE LA RECAPTACION DE SEROTONINA

    Farmacia Hospitalaria, Vol. 20, Núm. 2, pp. 73-85

  3. Interaccion de diltiazem con farmacos antiepilepticos

    Farmacia Hospitalaria

1994

  1. Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data

    Therapeutic Drug Monitoring, Vol. 16, Núm. 4, pp. 380-387

1993

  1. Dosage programming of phenobarbital in neonatal seizures

    Journal of Clinical Pharmacy and Therapeutics, Vol. 18, Núm. 4, pp. 267-270